Latest Distribution Partnerships News

Page 1 of 12
McKesson delivered a strong fiscal second quarter, with revenue up 8% and adjusted diluted EPS rising 18%. The healthcare distributor lifted its full-year adjusted EPS guidance while expanding its specialty-care portfolio through new investments and acquisitions.
Ada Torres
Ada Torres
5 Nov 2026
Proteomics International has launched a discounted A$5 million share purchase plan as it moves from product development into commercial rollout. Eligible shareholders can buy shares at A$0.10 and may receive a free attaching option, subject to approval.
Ada Torres
Ada Torres
2 Nov 2026
Osteopore reported record quarterly revenue of A$859,000 in Q3 CY26 as it added market access in Thailand and Saudi Arabia and completed its first customised Hainan implant. The regenerative implant maker remains cash-flow negative, with A$712,000 in cash and A$14 million still available under its convertible note facility.
Victor Sage
Victor Sage
30 Oct 2026
Doctor Care Anywhere’s Q3 revenue rose 16% to £11.3 million as its weight-management business delivered its first full quarter, lifting subscription revenue to 19% of the total. The unaudited update also shows modest consultation growth, higher cash and three new distribution partnerships.
Ada Torres
Ada Torres
30 Oct 2026
Jatcorp’s revenue rose 23% to $38.9 million in FY2026, but weaker margins, negative operating cash flow and a material going-concern uncertainty leave the nutritional products maker’s recovery unfinished. The company ended the year with $5.6 million in cash after a $4.2 million entitlement offer, while Neurio trademark litigation in China remains unresolved.
Victor Sage
Victor Sage
22 Oct 2026
De.mem has reported its strongest quarterly operating cash flow on record, with September cash receipts rising 29% year on year to approximately $10.1 million. The water treatment company also secured an $800,000 antiscalant framework agreement and two equipment orders due for delivery in 2027.
Victor Sage
Victor Sage
12 Oct 2026
Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.
Ada Torres
Ada Torres
31 Aug 2026
AML3D Limited surged to a record $12.5 million revenue in FY26, delivering its first half-year EBITDA profit and locking in a $29 million order book driven by US Defence contracts and UK market entry.
Victor Sage
Victor Sage
31 Aug 2026
Jatcorp Limited's FY26 results show a 23% revenue increase to $38.9 million but a 41% larger loss attributable to owners. The company faces a material uncertainty over going concern despite improved statutory NPAT.
Victor Sage
Victor Sage
28 Aug 2026
Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.
Ada Torres
Ada Torres
26 Aug 2026
Biome Australia has delivered a standout FY26 with sales up 30% to $23.9 million and net profit after tax soaring to $3.6 million, bolstered by a non-cash deferred tax asset. The company strengthened its balance sheet while expanding manufacturing and international distribution.
Ada Torres
Ada Torres
26 Aug 2026
ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.
Ada Torres
Ada Torres
29 July 2026

Browse the archive

Full archive